QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
Clinical trial NCT07601178 · RECRUITING
Trial details
- NCT number
- NCT07601178
- Sponsor
- Jiangsu Cancer Institute & Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-17
- Primary completion
- 2027-09-15
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.